3/10
07:42 am
sngx
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency [Yahoo! Finance]
Low
Report
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency [Yahoo! Finance]
3/10
07:30 am
sngx
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Low
Report
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
2/26
07:45 am
sngx
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease [Yahoo! Finance]
Low
Report
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease [Yahoo! Finance]
2/26
07:30 am
sngx
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
High
Report
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
2/24
07:54 am
sngx
Soligenix to Present at BIO Investment & Growth Summit [Yahoo! Finance]
Medium
Report
Soligenix to Present at BIO Investment & Growth Summit [Yahoo! Finance]
2/24
07:30 am
sngx
Soligenix to Present at BIO Investment & Growth Summit
Medium
Report
Soligenix to Present at BIO Investment & Growth Summit
2/12
07:30 am
sngx
Soligenix Details Recent Progress and Upcoming Milestones
Low
Report
Soligenix Details Recent Progress and Upcoming Milestones
1/24
05:10 am
sngx
Soligenix (NASDAQ:SNGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Soligenix (NASDAQ:SNGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/22
11:03 am
sngx
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
Low
Report
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
12/18
08:12 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
12/18
07:30 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
12/17
07:41 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
12/17
07:30 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis